In 2016, we conducted a materiality assessment to determine the ESG topics most important to our stakeholders and to inform our reporting and initiatives moving forward. In 2019, we completed a materiality refresh to reassess and reprioritize what our internal and external stakeholders consider to be the ESG topics posing the greatest opportunities and risks to our business, taking into consideration changes in stakeholder preferences and current events. We used the Six Capitals of Integrated Reporting as part of the refresh, and we carefully considered the issues and potential impacts to Edwards and its stakeholders and the potential significance of those impacts.Edwards Lifesciences Corporation (“Edwards”) is committed to the highest standards of ethical conduct. To meet this commitment, Edwards has implemented this Global Integrity Program based upon recognized government standards for effective compliance programs, including guidance published by the Office of Inspector General, U.S. Department of Health and Human Services (the “HHS-OIG Guidance”). The purpose of this Program is to detect and prevent behaviors, such as violations of law or company policy, which could harm Edwards and the people we serve. While the implementation of such a program cannot guarantee that improper employee conduct will be entirely eliminated, it is Edwards’ expectation that employees will comply with Program requirements, including the Edwards Global Business Practice Standards (“Standards”) and the policies and procedures established in support of the Standards. In the event that Edwards becomes aware of violations of law or company policy, we will investigate the matter and, where appropriate, take disciplinary action and implement corrective measures to prevent future violations.At Edwards, we build our success from a foundation of integrity and dedication to our Credo. Edwards has demonstrated leadership in ethical behavior and compliant business practices, and stakeholders stress the importance of maintaining that culture, reputation, and legacy. In our work developing life-saving therapies, our leadership and employees know every decision matters, no matter how small.Edwards specializes in heart valve technologies and therapies. Its focus on innovative medical devices, along with its strong market position, contributes to its financial stability. Edwards generates revenue from the sales of its heart valve products and related technologies. The company’s leadership in the cardiac care market, particularly in the field of transcatheter heart valve replacements, contributes to its revenue growth. Edwards’ products improve patient outcomes by addressing critical heart conditions and enabling less invasive procedures.Edwards’ Global Compliance Program supports our commitment to transforming patient lives with breakthrough medical technologies, excelling as a trusted partner through distinguished quality and integrity, and delivering exceptional value to our stakeholders. Driving a culture of integrity that promotes ethical behavior and compliance with our code of conduct, as well as with relevant laws and regulations, including anti-bribery and corruption.